Jacob Johnson
Stock Analyst at Stephens & Co.
(2.86)
# 1,822
Out of 4,996 analysts
75
Total ratings
45.76%
Success rate
9.02%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $249.08 | -3.65% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $8.01 | -25.09% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.01 | -14.41% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $28.54 | +110.23% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $184.84 | +70.42% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $464.24 | +46.48% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $125.61 | +35.34% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $6.07 | -17.63% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.53 | +618.95% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $25.66 | +48.09% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.20 | +84.78% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.44 | +73.61% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $51.84 | +67.82% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $261.52 | +49.13% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $7.93 | +126.99% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.46 | +143.90% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $24.70 | +17.41% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $148.56 | +153.77% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $249.08
Upside: -3.65%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $8.01
Upside: -25.09%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.01
Upside: -14.41%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $28.54
Upside: +110.23%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $184.84
Upside: +70.42%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $464.24
Upside: +46.48%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $125.61
Upside: +35.34%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $6.07
Upside: -17.63%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.53
Upside: +618.95%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $25.66
Upside: +48.09%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.20
Upside: +84.78%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.44
Upside: +73.61%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $51.84
Upside: +67.82%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $261.52
Upside: +49.13%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $7.93
Upside: +126.99%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.46
Upside: +143.90%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $24.70
Upside: +17.41%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $148.56
Upside: +153.77%